Reference:
Pfizer. (2022). Cumulative and interval summary tabulation of serious and non-serious adverse reactions from post-marketing data sources BNT162B2.
Summary:
The document presents a comprehensive analysis of cumulative and interval data on serious and non-serious adverse reactions associated with the BNT162B2 vaccine up to June 18, 2022. It details a total of 1,485,027 cases cumulatively, with 507,683 cases reported in the interval from December 19, 2021, to June 18, 2022. The total adverse events reported reached 4,964,106, with a significant number of cases categorised under various system organ classes. The findings highlight specific adverse events, such as anaemia, coagulation disorders, and cardiac issues, showcasing the diverse range of reported reactions. The analysis emphasises the importance of ongoing monitoring and reporting to ensure vaccine safety.